Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Samsung Pharmaceutical Co., Ltd. is a prominent entity in the pharmaceutical industry, primarily engaged in the research, development, and manufacturing of pharmaceutical and healthcare products. This company plays a key role in addressing diverse healthcare needs by producing a variety of drugs and medical solutions, which include over-the-counter medications, prescription drugs, and other specialized therapeutic products. Samsung Pharmaceutical operates at the intersection of science and healthcare, striving to enhance patient outcomes and overall public health. The company is recognized for its commitment to innovation and quality, leveraging advanced technology and rigorous scientific research to develop effective medical treatments. Operating within highly regulated markets, the company ensures compliance with stringent pharmaceutical standards and regulations, thus maintaining credibility and trust among healthcare professionals and consumers alike. As part of its broader impact, Samsung Pharmaceutical contributes to the healthcare sector by addressing unmet medical needs and supporting the advancement of medical science. It is a significant player in the pharmaceutical market, influencing drug pricing, healthcare access, and fostering pharmaceutical advancements across various regions.
€1,315.00
€24.00 (-1.79%)
Live · 05:26 PM
The business is unprofitable at the operating level (-39.22% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 4.0%, steady but not accelerating. Margins contracted 5.7pp, which offsets some of the top-line progress.
Negative free cash flow of -₩22.81B. The business is consuming cash, not generating it. Operating margin contracted 5.7pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩43.73B
▲ +4.0% YoY
Net Income (TTM)
-₩16.94B
▲ +181.9% YoY
Op. Margin
-35.37%
▼ -5.7pp YoY
ROIC
-11.43%
▲ +1.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-₩21.76B
▼ -29.1% YoY
Op. Cash Flow (TTM)
₩57.56B
▲ +180.5% YoY
Net Debt
₩1.53B
Cash & Equiv.
₩16.17B
3Y CAGR: -3.8%
Continue Research
Samsung Pharmaceutical Co. (001360.XKRX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Samsung Pharmaceutical Co. scores 0/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Samsung Pharmaceutical Co. scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -35.4% operating margin and a -11.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh 001360.XKRX's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.